Teva Proves GSK Unit's HIV Drug Patent Not Specific Enough
Teva has persuaded European officials to revoke an HIV antiviral therapy patent belonging to a joint GlaxoSmithKline and Pfizer unit after proving that it was not clear from the patent's parent...To view the full article, register now.
Already a subscriber? Click here to view full article